KESTRA MEDICAL TECHNOLOGIES, LTD.
KMTS scores 37.0 on the Conservative profile, blending a fundamental score (80% weight, emphasizing quality and stability (84% of fundamental weight)) with a machine-learning signal (20% weight) trained on 82 features across 30 years of data.
Net penalties of -14.7 points significantly impact the ranking. Without these adjustments, KMTS would rank considerably higher.
These features are direct inputs to the machine learning model. The model was trained on these signals alongside 100 features (including 12 momentum/technical indicators) to produce the ML percentile score.
| Stock | Score | P/E | Rev Growth | Margin | Mkt Cap |
|---|---|---|---|---|---|
| KMTS | 37.0 | N/A | 115.1% | -178.0% | $1.5B |
| INCY | 89.6 | 15.8 | 21.2% | 25.0% | $19.6B |
| GMAB | 85.6 | 13.1 | 22.8% | 36.4% | $17.9B |
| CPRX | 82.1 | 13.7 | 23.5% | 37.6% | $3.0B |
| VRTX | 78.0 | 32.1 | 8.9% | 32.9% | $121.8B |
| ASND | 75.8 | 16.6 | 98.0% | -31.7% | $13.8B |
| NBIX | 74.8 | 26.5 | 21.4% | 16.7% | $13.1B |
| AMGN | 73.9 | 26.0 | 10.0% | 21.0% | $204.8B |
| ARGX | 73.5 | 35.1 | 78.6% | 38.0% | $47.4B |
| HOLX | 73.3 | 31.1 | 1.7% | 13.8% | $16.8B |
| REGN | 72.4 | 19.4 | 1.0% | 31.4% | $80.2B |
| ISRG | 72.2 | 61.7 | 20.5% | 28.4% | $180.9B |
| EXEL | 71.6 | 15.1 | 7.0% | 33.7% | $11.9B |
| ALKS | 71.5 | 16.5 | -6.4% | 23.9% | $5.0B |
| KRYS | 71.0 | 41.4 | 473.0% | 30.7% | $7.9B |
| HALO | 70.3 | 16.8 | 22.4% | 43.7% | $8.2B |
| Sector Average | 37.0 | 41.9 | 161.5% | -3292.7% | โ |
Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. The company develops and commercializes Cardiac Recovery System platform, a system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. Its Cardiac Recovery System platform is the ASSURE WCD, a wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). The company's Cardiac Recovery System platform also includes a suite of integrated digital solutions and services that enable enhanced patient and provider engagement and oversight with the objective of improving patient outcomes. The company was founded in 2014 and is based in Kirkland, Washington.
Stock is losing momentum near highs. The 200-day SMA is flattening or beginning to turn. Historically, this stage precedes distribution.
| Metric | Q2 2025 | Q1 2025 | Q4 2025 | Q3 2025 |
|---|---|---|---|---|
| Revenue | $23M | $19M | $17M | $15M |
| Gross Profit | $11M | $9M | $8M | $7M |
| Operating Income | $-32M | $-29M | $-48M | $-21M |
| Net Income | $-33M | $-26M | $-52M | $-22M |
| EPS (Diluted) | $-0.64 | $-0.50 | $-2.21 | $-0.50 |
| Gross Margin | 50.6% | 45.7% | 44.3% | 43.4% |
| Operating Margin | -140.7% | -149.1% | -279.8% | -136.5% |
| Net Margin | -145.3% | -133.3% | -302.1% | -142.5% |
Growth estimates have been dampened based on technical and fundamental signals. This is a post-hoc adjustment to prevent overly optimistic projections for stocks showing declining momentum or deteriorating fundamentals.
Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.